Ultragenyx Secures FDA Nod for First-Ever Sanfilippo Syndrome Type A Gene Therapy
Event summary
- Ultragenyx's FAYUVI™ (rebisufligene etisparvovec-hopf) received FDA approval on September 17, 2026, becoming the first treatment for Sanfilippo Syndrome Type A (MPS IIIA).
- The therapy is a single-dose intravenous AAV9 gene therapy designed to deliver a functional copy of the deficient enzyme gene.
- Ultragenyx received a Priority Review Voucher upon approval, marking its second gene therapy approval and sixth FDA approval overall.
- Commercial product availability is expected within 30-60 days, with support through the UltraCare® program for patient access.
The big picture
Ultragenyx's FDA approval for FAYUVI represents a significant milestone in the gene therapy space, particularly for treating ultra-rare neurodegenerative diseases. The approval underscores the growing viability of gene therapies for conditions with high unmet medical needs, potentially opening doors for other similar treatments in development. The strategic shift towards rare disease therapies highlights Ultragenyx's focus on addressing conditions with clear biological targets and limited treatment options.
What we're watching
- Commercialization Pace
- The pace at which Ultragenyx can ship FAYUVI to Qualified Treatment Centers and secure insurance coverage will determine early adoption rates.
- Therapeutic Efficacy
- Long-term data on FAYUVI's ability to slow or halt neurologic progression in Sanfilippo Syndrome Type A patients will be critical for sustained market acceptance.
- Pipeline Expansion
- Whether Ultragenyx can leverage this approval to accelerate other ultra-rare gene therapy candidates in its pipeline.